Oncolytics Biotech Reports ~15-Month Response Duration in Anal Cancer Study
Cohort 4 GOBLET data showed a median response duration of ~15 months in second-line-plus anal cancer, versus 9.5 months historically for approved retifanlimab monotherapy. All responders survived beyond 12 months. The company said FDA Fast Track supports a path to registration.